Abstract

ObjectiveThe purpose of this study was to determine the effect of beta-trace protein (BTP) levels at the time of admission and at 8th hour on diagnosis and prognosis in patients who were under treatment and follow-up with acute coronary syndrome (ACS) diagnosis at coronary intensive care unit and emergency department.Materials and MethodsThis study was conducted between June 2014 and December 2014 at the Emergency Department of Konya Training and Research Hospital. Demographic characteristics, background, vital findings, laboratory findings, blood BTP levels, coronary angiography results, and echocardiography findings of the patients diagnosed with ACS were recorded. Risk classification was performed for patients with ACS and their mortality rates were recorded. Relation of BTP level with risk classification and mortality was evaluated.ResultsA total of 174 individuals, 138 patients and 36 control subjects, were included in the study. No significant difference was detected between BTP levels at the time of admission and at 8th hour in the patient group (p=0.883). There was no difference between the patient and control groups in terms of the BTP level (p=0.335). Ten patients (7.2%) died in the patient group. BTP levels measured at the time of admission and at 8th hour were not different for dead and living patients (admission p=0.085, 8th hour p=0.141).ConclusionWe determined that there was a lack of biochemical markers that could be used for the prognosis of serum BTP levels in patients admitting to the emergency unit with ACS.

Highlights

  • Beta-trace protein (BTP), known as prostaglandin D synthase (PGDS), is a protein with a low molecular weight that belongs to the lipocalin protein family

  • We aimed to determine the effect of serum BTP levels on diagnosis and prognosis in patients presenting to the emergency service with acute coronary syndrome (ACS)

  • Patients with ≥50% stenosis according to coronary angiography (CAG) results were considered as having a significant coronary artery disease (CAD), and those with ≤50% stenosis were regarded as having non-critical stenosis

Read more

Summary

Introduction

Beta-trace protein (BTP), known as prostaglandin D synthase (PGDS), is a protein with a low molecular weight that belongs to the lipocalin protein family. In various studies involving human and animal models, BTP has been demonstrated to play a protective role in the heart under hypoxia and ischemia [6]. It has a biological role in vasodilatation, bronchoconstriction, thrombocyte aggregation inhibition, and inflammatory cell processes [7]. These findings suggest that BTP may play a role in the pathophysiology of cardiovascular diseases. We aimed to determine the effect of serum BTP levels on diagnosis and prognosis in patients presenting to the emergency service with acute coronary syndrome (ACS)

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call